All patients who present to the neonatal intensive care unit at BIDMC who require intravenous nutritional support and provide informed consent will be included in the study. The decision to initiate intravenous nutritional support will be made by clinical personnel, and the dosing protocol for lipid injectable emulsion will follow institutional procedures as shown above in B3 (Description of Study Protocol) (section1-a). Patients will be randomized to receive one of two study parenteral lipid emulsions. As hydrocortisone therapy is rarely used in the treatment of refractory hypotension in neonates, and has been shown to induce hypertriglyceridemia in very low birth weight infants (younger than 29 weeks' gestational age at birth), such patients will be excluded from study. Due to randomization, patients enrolled in either group are expected to be similarly distributed with respect to gestational age, gender and race.